Bemsivir sent to Pakistan by Beximco Pharmaceuticals for Covid-19 patients by exclusive cargo flight as the coronavirus treatment drug.
Coronavirus treatment drug sends by Bangladesh Pharma to Pakistan to treat coronavirus patients. Bangladeshi-based pharmaceutical company has sent drug to support treat critical Covid-19 patients.
Beximco spoke persons said the medicine was sent to Pakistan on demand of the Pakistan High Commission in Dhaka for three critically ill Covid-19 patients. Beximco sent 48 injections of Bemsivir on humanitarian basis.
Bemsivir is the the world’s first accepted generic Remdesivir – was sent for a small group of critically ill patients against special import license given by Pakistan Drug Regulatory Authority.
Previous, Reuters stated that a medicinal company in Pakistan had planned to import the antiviral drug remdesivir, which has shown promise in treating coronavirus patients, from neighboring Bangladesh.
The statement by Searle Company Limited appeared a day after 56 virus deaths verified by Pakistan in a single day.
The firm said it had entered into an exclusive licensing and marketing agreement with Bangladesh’s Beximco Pharmaceuticals, the first company in the world to introduce the generic variant of the drug.
Searle Pharma is forecasting to import remdesivir in complete form (ready to use) to meet the country’s imperative requirements, the company told the Pakistan Stock Exchange.
Remdesivir, a drug developed by Gilead Sciences, has grasped attention as one of the most guaranteeing treatments for Covid-19, the respirational disease caused by the virus, which has killed more than 350,000 people worldwide.
Ferozson’s Pharma said they would make the drug in Pakistan after signing a non-exclusive licensing agreement with Gilead to make and sell the drug to 127 nations, but it notified that production could take weeks.
Searle said, Bangladesh imports would guarantee instant supply of the drug at reasonable price, helping to eradicate treatment delays by Pakistan’s healthcare providers.
Patent of Gilead gives the US company exclusive rights to make the antiviral. But universal trade rules allow nations defined by the United Nations as least-developed countries (LDCs) to ignore the patent and make such drugs more inexpensive in their markets.
Bangladesh is one of 47 countries that fall in this category.